LATEST
WEBSTORY
TRENDING

DNA Exclusive: Check LSS score of Jitin Prasada, BJP candidate from Uttar Pradesh's Pilibhit

Yavatmal-Washim Lok Sabha constituency: Check polling date, candidates list, past election results

IPL 2024: KKR star Rinku Singh finally gets another bat from Virat Kohli after breaking previous one - Watch

Bowlers with most wides in IPL history

Benefits of drinking barley water

Butter vs Ghee vs Oil: Which is healthier?

BJP appoints new state presidents in Telangana, Jharkhand, Punjab, Andhra ahead of 2024 Lok Sabha polls

Meet 'mystery girl' whose pictures with Indian cricketer Yuzvendar Chahal is going viral

SCO must not hesitate to criticise countries supporting terrorism: PM Modi

PHOTOS
VIDEOS
ENTERTAINMENT

Actors who died due to cosmetic surgeries

See inside pics: Malayalam star Aparna Das' dreamy wedding with Manjummel Boys actor Deepak Parambol

In pics: Salman Khan, Alia Bhatt, Rekha, Neetu Kapoor attend grand premiere of Sanjay Leela Bhansali's Heeramandi

Karnataka Horror: Congress Leader's Daughter Stabbed To Death On College Campus In Hubballi

Manipur: Firing At Polling Booth, Voters Run For Cover | Lok Sabha Elections 2024

Israel Launches Missile Attack on Iran's Isfahan In Response To Iranian Assault | Breaking News

Harvey Weinstein's rape conviction in 2020 #MeToo case overturned by New York court

Laapataa Ladies OTT release: Here's when and where you can enjoy Kiran Rao's critically acclaimed film

Lyricist Raj Shekhar talks about writers' rights in Bollywood, says Indians won't strike like in Hollywood | Exclusive

Home Business

Business

AstraZeneca's asthama drug fails in study

The drug failed to meet the goal of significantly reducing the annual asthama exacerbation rate in a late-stage study.

DNA Web Team

Updated : Mar 25, 2018, 04:58 AM IST

Drugmaker AstraZeneca Plc said its asthma drug failed to meet the main goal of significantly reducing the annual asthma exacerbation rate in a late-stage study.

The drug, tralokinumab, failed against placebo, the company said, adding that it would now await the results from a second round of late-stage trial of the drug in the second half of the year.

Asthma affects about 315 million people worldwide, with about 10% suffering from severe asthma, the company said.

REUTERSONLINE-NEWS

Find your daily dose of news & explainers in your WhatsApp. Stay updated, Stay informed- Follow DNA on WhatsApp.